Methods of treating covid-19 mediated lung damage using surfactants and natural antibodies
OwnerGhassan S Kassab, Carlos A Labarrereinventors
Life of this patent
Estimating the term…
Abstract
Disclosed is a method of treating respiratory viruses including coronaviruses such as SARS-CoV-2 using surfactant, surfactant protein A and/or surfactant protein D. The surfactant and surfactant protein treatment can be used in combination with immunoglobulin M administered intravenously. Surfactant proteins used in these embodiments, especially surfactant protein D, can be harvested from an exogenous source such as pigs, as they show improved resilience against viruses.
Claims20
A method of treating a mammalian patient infected with a respiratory virus comprising the step of administering a therapeutically effective amount of surfactant protein.
A method of treating a human patient infected with a severe acute respiratory syndrome coronavirus or a variant thereof, comprising the step of administering a therapeutically effective amount of surfactant and porcine SP-D and SPD-A.
A method of treating a human patient infected with a severe acute respiratory syndrome coronavirus or a variant thereof, comprising the step of administering a therapeutically effective amount of SP-D.
Dependencies are inferred from the claim text.